R
Ruben P A van Eijk
Researcher at Utrecht University
Publications - 90
Citations - 1645
Ruben P A van Eijk is an academic researcher from Utrecht University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 15, co-authored 62 publications receiving 811 citations. Previous affiliations of Ruben P A van Eijk include University Medical Center Utrecht & Oklahoma State University Center for Health Sciences.
Papers
More filters
Journal ArticleDOI
Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model
Henk Jan Westeneng,Thomas P. A. Debray,Anne E. Visser,Ruben P A van Eijk,James Rooney,Andrea Calvo,Sarah Martin,Christopher J McDermott,Alexander G. Thompson,Susana Pinto,Xenia Kobeleva,Angela Rosenbohm,Beatrice Stubendorff,Helma Sommer,Bas M. Middelkoop,Annelot M. Dekker,Joke van Vugt,Wouter van Rheenen,Alice Vajda,Mark Heverin,Mbombe Kazoka,Hannah Hollinger,Marta Gromicho,Sonja Körner,Thomas M. Ringer,A. Rödiger,A. Gunkel,Christopher Shaw,Annelien L. Bredenoord,Michael A van Es,Philippe Corcia,Philippe Couratier,Markus Weber,Julian Grosskreutz,Albert C. Ludolph,Susanne Petri,Mamede de Carvalho,Philip Van Damme,Kevin Talbot,Martin R Turner,Pamela J. Shaw,Ammar Al-Chalabi,Adriano Chiò,Orla Hardiman,Orla Hardiman,Karel G.M. Moons,Jan H. Veldink,Leonard H. van den Berg +47 more
TL;DR: An externally validated model is developed to predict survival without tracheostomy and non-invasive ventilation for more than 23 h per day in European patients with ALS and could be applied to individualised patient management, counselling, and future trial design.
Journal ArticleDOI
Hypermetabolism in ALS is associated with greater functional decline and shorter survival.
Frederik J. Steyn,Zara A. Ioannides,Ruben P A van Eijk,Susan Heggie,Kathryn A Thorpe,Amelia Ceslis,Saman Heshmat,Anjali K. Henders,Naomi R. Wray,Naomi R. Wray,Leonard H. van den Berg,Robert D. Henderson,Pamela A. McCombe,Shyuan T. Ngo +13 more
TL;DR: Hypermetabolic patients with ALS have a greater level of lower motor neuron involvement, faster rate of functional decline and shorter survival, and the metabolic index could be important for informing prognosis in ALS.
Journal ArticleDOI
Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials
Ruben P A van Eijk,Ashley R. Jones,William Sproviero,Aleksey Shatunov,Pamela J. Shaw,P. Nigel Leigh,Carolyn A Young,Christopher Shaw,Gabriele Mora,Jessica Mandrioli,Giuseppe Borghero,Paolo Volanti,Frank P. Diekstra,Wouter van Rheenen,Esther Verstraete,Marinus J.C. Eijkemans,Jan H. Veldink,Adriano Chiò,Ammar Al-Chalabi,Leonard H. van den Berg,Michael A. van Es,For UKMND-LiCALS +21 more
TL;DR: The results suggest that the strategies toward finding treatments for ALS should reorient, start focusing on genotype-targeted treatments, and standardize genotyping in order to optimize randomization and analysis for future clinical trials.
Journal ArticleDOI
Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials
Ruben P A van Eijk,Henk Jan Westeneng,Stavros Nikolakopoulos,Iris E. Verhagen,Michael A. van Es,Marinus J.C. Eijkemans,Leonard H. van den Berg +6 more
TL;DR: The majority of patients with ALS are excluded from trial participation, which questions the generalizability of trial results, and an individualized risk-based criterion could be used to balance the gains in trial design and loss in generalIZability.
Journal ArticleDOI
Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials
Ruben P A van Eijk,Marinus J.C. Eijkemans,Toby A. Ferguson,Stavros Nikolakopoulos,Jan H. Veldink,Leonard H. van den Berg +5 more
TL;DR: Plasma creatinine is an inexpensive and easily accessible biomarker that exhibits less variability between patients with ALS over time and is predictive for the patient’s functional status, muscle strength and mortality risk.